PHATHOM PHARMACEUTICALS INC
NASDAQ: PHAT (Phathom Pharmaceuticals, Inc.)
Last update: 14 hours ago14.56
-0.29 (-1.95%)
| Previous Close | 14.85 |
| Open | 14.45 |
| Volume | 971,481 |
| Avg. Volume (3M) | 1,157,179 |
| Market Cap | 1,056,405,824 |
| Price / Sales | 7.05 |
| 52 Weeks Range | |
| Earnings Date | 30 Oct 2025 |
| Operating Margin (TTM) | -276.53% |
| Diluted EPS (TTM) | -5.18 |
| Quarterly Revenue Growth (YOY) | 1,391.60% |
| Current Ratio (MRQ) | 3.58 |
| Operating Cash Flow (TTM) | -282.68 M |
| Levered Free Cash Flow (TTM) | -201.84 M |
| Return on Assets (TTM) | -55.01% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Phathom Pharmaceuticals, Inc. | Bullish | Bearish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | -3.0 |
| Price Volatility | -5.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | -0.90 |
|
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 4.28% |
| % Held by Institutions | 84.77% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Ensign Peak Advisors, Inc | 30 Sep 2025 | 2,503,344 |
| 683 Capital Management, Llc | 30 Sep 2025 | 1,820,380 |
| Wasatch Advisors Lp | 30 Sep 2025 | 1,537,218 |
| Catalys Pacific, Llc | 30 Sep 2025 | 1,167,114 |
| Catalio Capital Management, Lp | 30 Sep 2025 | 1,128,521 |
| 52 Weeks Range | ||
| Median | 26.00 (78.57%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 31 Oct 2025 | 26.00 (78.57%) | Buy | 13.55 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| BREEDLOVE ROBERT CHARLES | - | 13.73 | -524 | -7,195 |
| Aggregate Net Quantity | -524 | |||
| Aggregate Net Value ($) | -7,195 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 13.73 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| BREEDLOVE ROBERT CHARLES | Officer | 03 Nov 2025 | Sell (-) | 524 | 13.73 | 7,195 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |